-$1.35 Earnings Per Share Expected for Clovis Oncology (CLVS) This Quarter

Wall Street analysts expect that Clovis Oncology (NASDAQ:CLVS) will post ($1.35) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Clovis Oncology’s earnings. The highest EPS estimate is ($1.11) and the lowest is ($1.53). Clovis Oncology reported earnings per share of ($1.13) during the same quarter last year, which would suggest a negative year-over-year growth rate of 19.5%. The company is expected to announce its next earnings report on Wednesday, May 2nd.

According to Zacks, analysts expect that Clovis Oncology will report full-year earnings of ($4.81) per share for the current financial year, with EPS estimates ranging from ($5.87) to ($2.82). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.88) per share, with EPS estimates ranging from ($4.67) to $0.31. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Clovis Oncology.

How to Become a New Pot Stock Millionaire

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The firm had revenue of $17.04 million for the quarter, compared to the consensus estimate of $19.42 million. During the same quarter last year, the business posted ($1.83) earnings per share. The firm’s revenue was up 21746.2% compared to the same quarter last year.

A number of brokerages recently commented on CLVS. ValuEngine downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 11th. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, February 27th. SunTrust Banks reduced their price objective on Clovis Oncology from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reduced their price objective on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $87.60.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the sale, the insider now owns 180,571 shares in the company, valued at approximately $9,767,085.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the sale, the director now owns 16,618 shares in the company, valued at approximately $997,080. The disclosure for this sale can be found here. Insiders sold a total of 16,500 shares of company stock worth $978,975 in the last quarter. Company insiders own 12.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of CLVS. Palo Alto Investors LLC grew its stake in Clovis Oncology by 2.2% during the 4th quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock worth $231,389,000 after purchasing an additional 73,200 shares in the last quarter. Franklin Resources Inc. grew its stake in Clovis Oncology by 13.8% during the 4th quarter. Franklin Resources Inc. now owns 2,634,401 shares of the biopharmaceutical company’s stock worth $179,138,000 after purchasing an additional 318,931 shares in the last quarter. Redmile Group LLC grew its stake in Clovis Oncology by 32.5% during the 4th quarter. Redmile Group LLC now owns 1,320,027 shares of the biopharmaceutical company’s stock worth $89,762,000 after purchasing an additional 323,417 shares in the last quarter. Alliancebernstein L.P. grew its stake in Clovis Oncology by 4.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,002,897 shares of the biopharmaceutical company’s stock worth $68,197,000 after purchasing an additional 41,120 shares in the last quarter. Finally, HealthCor Management L.P. grew its stake in Clovis Oncology by 50.4% during the 4th quarter. HealthCor Management L.P. now owns 973,840 shares of the biopharmaceutical company’s stock worth $66,221,000 after purchasing an additional 326,420 shares in the last quarter.

Clovis Oncology stock traded down $0.90 during trading on Thursday, reaching $53.51. 4,027,687 shares of the company were exchanged, compared to its average volume of 1,337,168. Clovis Oncology has a 52-week low of $45.42 and a 52-week high of $99.45. The company has a market cap of $3,066.76, a price-to-earnings ratio of -10.64 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.35 and a current ratio of 7.69.

TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/04/17/1-35-earnings-per-share-expected-for-clovis-oncology-clvs-this-quarter.html.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply